医学
放射治疗
放化疗
肿瘤科
回顾性队列研究
免疫疗法
食管鳞状细胞癌
内科学
基底细胞
放射科
癌
癌症
作者
Hui-Hui Hu,Xin Xu,Xiaoyang Li,Ya Zeng,Yue Li,Xinyun Song,Xiaolong Fu,Xiumei Ma,Wen Yu
标识
DOI:10.1016/j.ctro.2024.100818
摘要
Chemotherapy plus immunotherapy has become the standard first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC), but median duration of response is only 7.0-8.3 months and progression-free survival (PFS, ∼6 months) is still far from satisfactory. We aim to evaluate whether early involvement of radiotherapy might improve the treatment outcome if objective response to first-line chemo-immunotherapy was observed in locally advanced or metastatic ESCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI